

UNIT LEVEL AT IMPLEMENTATION LYMPHATIC FILARIASIS TO ELIMINATE OF THE PROGRAMME ASSESSMENT EPIDEMIOLOGICAL MONITORING AND

**MONITORING AND
EPIDEMIOLOGICAL
ASSESSMENT
OF THE PROGRAMME
TO ELIMINATE
LYMPHATIC FILARIASIS
AT IMPLEMENTATION
UNIT LEVEL**



World Health
Organization

LYMPHATIC FILARIASIS

Monitoring and epidemiological assessment of the programme to eliminate lymphatic filariasis at implementation unit level

Monitoring and epidemiological assessment of the programme to eliminate lymphatic filariasis at implementation unit level

© World Health Organization 2005

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Preface	V
Acknowledgements	VII
Elimination of lymphatic filariasis as a public health problem	1
Strategy to eliminate lymphatic filariasis as a public health problem	1
<i>Interruption of transmission</i>	1
<i>Prevention of disability associated with lymphatic filariasis</i>	2
The importance of monitoring	2
<i>What should be monitored?</i>	2
<i>Which monitoring indicators are needed?</i>	2
Implementation unit (IU)	3
<i>Preliminary information on the lymphatic filariasis status of implementation units</i>	3
<i>Assessment of endemicity of lymphatic filariasis in the implementation unit</i>	3
<i>At-risk population in the implementation unit</i>	4
<i>How to calculate the total population of the implementation unit</i>	4
<i>Eligible population in the implementation unit</i>	4
Monitoring for an effective mass drug administration campaign	4
Monitoring the impact of mass drug administration on microfilaraemia	7
<i>Choice of diagnostic tool</i>	8
<i>Sampling and frequency of measurement</i>	8
The choice of sentinel and spot-check sites	8
<i>How many sentinel sites are needed for each implementation unit?</i>	9
<i>Characteristics of sentinel sites</i>	9
<i>Characteristics of spot-check sites</i>	9
<i>Size of population of sentinel and spot-check sites</i>	9
<i>Survey for baseline indicators</i>	10
<i>Prevalence and density of microfilariae in sentinel and spot-check sites</i>	10
<i>Measurement of clinical manifestations — prevalence of lymphoedema and hydrocele in sentinel sites</i>	12
Measuring the criteria for stopping mass drug administration	13
<i>Steps in deciding when to stop mass drug administration</i>	13
The passive surveillance system	17
Post-operations surveillance	17
Annex 1	19
<i>Introduction</i>	19
<i>Overview</i>	20
<i>Methods</i>	20
<i>Analysis</i>	23
Appendix	24
Annex 2: Table of random numbers	27
Annex 3: Example of population-proportionate sampling	29

Annex 4: Random selection of the starting household	33
<i>Randomly select a starting household from a list of all households in the subunit</i>	33
<i>Randomly select a starting household from a map of all households in the subunit. The map should ideally be updated in collaboration with a resident of the area who knows about recent changes</i>	33
<i>Divide the subunit into smaller units such as quadrants, and following random selection of one of these, prepare a list of households within the smaller unit and randomly select the starting household</i>	33
<i>Randomly select a direction of travel, and after counting all households in that direction of travel, randomly select a starting household</i>	34
Annex 5: Sample sizes for different anticipated coverage and design effects	35
Annex 6: Lot quality assurance sampling	37
<i>Community lot quality assurance cluster samples</i>	37
<i>Systematic sampling in schools</i>	37
<i>Dealing with ICT-positives</i>	37
<i>Smaller sample sizes</i>	38
Annex 7: Algorithm for following up positive immunochromatographic test results in surveys to determine whether or not to stop mass drug administration	39
Annex 8: Recommended procedures for the detection and identification of microfilariae in blood	41
<i>Preparation of a thick blood film for examining microfilariae</i>	42
<i>Staining of a thick blood film for examining microfilariae</i>	45
<i>Possible causes of misidentification</i>	47

PREFACE

The Global Programme to Eliminate Lymphatic Filariasis was launched in 2000 and since then has expanded its mass drug administration coverage with the recommended two-drug co-administration from 3 million people in 12 countries in 2000 to more than 70 million people in 36 countries in 2003.

Throughout this period, the need for standardized guidelines on monitoring and epidemiological assessment of the Programme at implementation unit level has become increasingly evident because this is the level at which the core programmatic operations are conducted. These guidelines are based on current knowledge and understanding of the epidemiological aspects of the disease. However, in view of the rapid evolvement of both scientific advances and experience in implementation of national elimination programmes, adaptation of the guidelines might be required to address particular circumstances.

In light of the diverse responsibilities of the health personnel in charge of lymphatic filariasis elimination programmes, the authors have developed guidelines that are as concise as possible. Annexes have been included to provide the most relevant technical background information while avoiding too much detail in the body of the guidelines.

Similar guidelines are planned to assist health personnel at the level of the implementation unit in other areas such as drug distribution, social mobilization and disability prevention and control.

ACKNOWLEDGEMENTS

These guidelines, the development of which was coordinated by Dr F. Rio, Lymphatic Filariasis Elimination (CEE/FIL), World Health Organization, are based on the recommendations of the Working Group on Monitoring and Evaluation set up by the Technical Advisory Group on Lymphatic Filariasis (TAG-ELF) comprising the following individuals.

Dr P.K. Das, Director, Vector Control Research Centre (VCRC), Pondicherry, India; Professor Dejian Sun, Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shanghai, China; Dr J. Gyapong, Health Research Unit, Ministry of Health, Accra, Ghana; Professor J.D.F. Habbema, Center for Decision Sciences in Tropical Disease Control, Department of Public Health, Erasmus University, Rotterdam, Netherlands; Dr R. Houston, LF Support Center, Emory University, Atlanta, GA, USA; Dr E.A. Ottesen, Director, LF Support Center, Emory University, Atlanta, GA, USA; Professor D. Molyneux, Director, LF Support Center, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; Dr G. Biswas, Lymphatic Filariasis Elimination (CEE/FIL), World Health Organization, Geneva, Switzerland; Dr S. Yactayo, Lymphatic Filariasis Elimination (CEE/FIL), World Health Organization, Geneva, Switzerland.

These recommendations were endorsed by TAG-ELF during its fourth meeting held from 25 to 28 March 2003 in Veyrier-du-Lac, Annecy, France. Subsequently, the recommendations were drafted by WHO staff and the Emory LF Support Center, Atlanta, USA and approved by TAG-ELF at its fifth meeting held in Geneva, Switzerland from 3 to 6 February 2004.

Editors: Ms S. Kaplan and Ms K. Ciceri

Layout: www.services-concept.ch, Geneva

预览已结束，完整报告链接和二维

<https://www.yunbaogao.cn/report/index/report?reportl>